Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

Healthy Postmenopausal Women Clinical Trial

Official title:
Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01Fand T121E02F in Healthy Postmenopausal Women

Status Completed

Clinical Trial Summary

THAR2011-1 is a Phase I, single dose, open-label dose-escalation study to determine the safety, absolute bioavailability, dose proportionality, and pharmacokinetics of T121 in healthy postmenopausal women. The study is expected to identify a safe dose that can be further tested in subsequent multiple dose studies comparing the safety, PK and pharmacodynamics (PD) of T121 with the currently marketed IV zoledronic acid (Zometa).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Healthy Postmenopausal Women

Clinical Trial Details

NCT number	NCT01721993
Study type	Interventional
Source	Thar Pharmaceuticals, Inc
Contact
Status	Completed
Phase	Phase 1
Start date	January 2013
Completion date	August 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01438073` - Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling	Phase 1
Not yet recruiting	`NCT06467201` - SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of KSHN001126 in Healthy Post-Menopausal Females	Phase 1
Completed	`NCT04000815` - Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods	N/A